Tradename: VYJUVEK

Proper Name: beremagene geperpavec-svdt

Indication: Indicated for treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.                  

Approval Date: 05/19/2023

Manufacturer: Krystal Biotech, Inc.


Leave a Reply

Your email address will not be published. Required fields are marked *